Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Alnylam is an early-stage biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. The company has no approved products and has not generated revenue from product sales. Operations are funded primarily through equity financing and strategic collaborations, notably with Merck & Co., Inc.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2005 |
Six Months Ended June 30, 2005 |
Six Months Ended June 30, 2004 |
|---|---|---|---|
| Net Revenues | $1,108 | $2,751 | $265 |
| Operating Expenses | $12,312 | $20,636 | $20,572 |
| Net Loss | $(11,145) | $(17,745) | $(20,538) |
| Cash and Cash Equivalents (End of Period) |
$9,165 (as of June 30, 2005) | ||
| Marketable Securities (End of Period) |
$22,477 (as of June 30, 2005) | ||
| Total Debt (Note Payable) (Current + Long-term) |
$7,963 (Principal) | ||
| Accumulated Deficit | $(80,750) (as of June 30, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased significantly to $1.1 million for the quarter (from $0.1 million in Q2 2004) and $2.8 million for the six months (from $0.3 million in the prior year). This growth is driven by cost-reimbursement revenues from the Merck ocular collaboration and amortization of upfront license fees.
- Operating Expenses: Total operating expenses rose 73% in the quarter to $12.3 million, primarily due to a 121% increase in Research and Development (R&D) expenses. R&D increased due to higher external service costs for RSV and AMD programs and a $2.1 million non-cash license fee expense related to a Garching Innovation GmbH agreement amendment.
- Liquidity: Cash and cash equivalents decreased from $20.3 million at year-end 2004 to $9.2 million at June 30, 2005. Net cash used in operating activities was $13.9 million for the six months ended June 30, 2005, compared to $14.9 million in the prior year period.
- Debt: The company maintains a $10.0 million equipment line of credit with Lighthouse Capital Partners. As of June 30, 2005, the outstanding principal balance was approximately $8.0 million.
Outlook, Risks, and Management Commentary
- Capital Resources: Management believes existing resources, combined with expected cash from alliances, are sufficient to fund operations through the end of 2006. However, the company expects to incur significant additional losses and will require substantial additional funding for clinical trials and product development.
- Development Pipeline: Key programs include Age-Related Macular Degeneration (AMD) and Respiratory Syncytial Virus (RSV). The company expects to begin a clinical trial for an AMD candidate in the second half of 2005 and an RSV candidate in the first half of 2006.
- Strategic Agreements:
- Merck: Two active collaborations (technology platform and ocular diseases) provide significant funding and cost-sharing.
- Garching: A June 2005 amendment required the issuance of 270,000 shares of common stock (valued at $2.1 million) to maintain exclusivity of certain patents.
- CFFT: A new collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. was initiated in March 2005.
- Risks:
- Technology Risk: RNAi is an unproven therapeutic approach; no siRNA-based drugs have received regulatory approval.
- Patent Litigation: Key patents (Kreutzer-Limmer series) are subject to opposition proceedings in the European and Australian Patent Offices, which could result in invalidation.
- Financing: Failure to secure additional funding could force the company to curtail research programs.
- Accounting Changes: The company will adopt SFAS 123R in 2006, which is expected to increase stock-based compensation expenses.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $31.6 million in liquid assets (cash + marketable securities) to fund operations through 2006 given the high burn rate.
- Patent Status: Monitor the outcome of opposition proceedings regarding the Kreutzer-Limmer patents in Europe and Australia, as these are critical to the company's exclusivity.
- Clinical Milestones: Track the initiation of the AMD clinical trial (expected H2 2005) and RSV trial (expected H1 2006) as key value drivers.
- Collaboration Terms: Review the specific milestones and payment triggers within the Merck and CFFT agreements to assess future revenue visibility.
- Stock-Based Compensation: Assess the potential impact of the upcoming adoption of SFAS 123R on future net loss figures.